摘要
[目的]探究不同级别颅脑胶质瘤患者肿瘤切除术后的细胞免疫状况。[方法]选择2012年1月至2013年1月本院收治的86例脑胶质瘤患者作为研究对象，按照恶性程度（WHO分级标准）分为两组，低级别组（Ⅰ～Ⅱ级）42例，高级别组（Ⅲ～Ⅳ级）44例，另选择同期在本院体检健康者40例作为正常对照组。胶质瘤患者术前1d、治疗后一周和正常对照组抽取外周血3mL，测定T淋巴细胞和自然杀伤细胞（NK细胞）的水平，比较不同级别胶质瘤患者上述指标的差异。86例胶质瘤患者分为CD4＋／CD8＋〉1（n=48）和CD4＋／CD8＋G1（n=38），进行生存分析，比较两组差异。[结果]胶质瘤患者外周血CD3＋、CD4＋、CD4＋／CD8＋、NK细胞（CD56＋）显著低于正常对照组，CD8＋显著高于正常对照组，差异有统计学意义（PG0．05）；手术前、后低级别胶质瘤组CD4＋／CD8＋显著高于高级别胶质瘤组，CD8＋低于高级别胶质瘤组（P〈0．05），而CD3＋、CD4＋、NK细胞（CD56＋）无统计差异（P〉0．05）；低级别胶质瘤组中位生存期32个月，高级别胶质瘤组中位生存期15个月，两组间差异有统计学意义（PG0．05）；CD4＋／CD8＋〉1组中位生存期30个月，CD4＋／CD8＋〈1组中住生存期14个月，两组间差异有统计学意义（PG0．05）。[结论]胶质瘤患者恶性程度越高，机体免疫功能越低，生存期缩短，预后较差；术前外周血T淋巴细胞亚群检测可为评估胶质瘤恶性程度及患者预后的提供参考。
[Objective]To explore the cellular immune status of patients with different levels of cerebral gliomas after tumor resection.[Methods]Eighty-six cases of glioma patients admitted to the Neurosurgery of the hospital from January 2012 to January 2013 were selected as the study objects. In accordance with the degree of malignancy of gliomas （WHO grading standards） they were divided into two groups, low-level group （Ⅰ-Ⅱ grade） with 42 cases, and the high-level group （Ⅲ-Ⅳgrade） with 44 cases. 40 healthy people were picked up from people taking physical examination at the same period as normal/control group. One day before surgery and one week after treatment, patients with glioma and people of the control group were extracted from peripheral blood of 3 mL to determine the levels of T lymphocytes and natural killer cells （NK cells）, and to compare the differences of the above indexes in patients with different levels of glioma. 86 pa tients with glioma were divided into CD4＋/CD8＋〉1 group（ n =48）and CD4＋/CD8＋ ;lgroup（ n = 38）, and the sur- vival analysis was conducted to compare the difference between the two groups.[ResultslPeripheral blood CD3＋ , CIN＋ , CD4＋/CD8＋ , NK cells （CD56 ＋ ） of glioma patients were significantly lower than those of the control group, CD8＋ was significantly higher than that of the control group, the difference was statistically significant （ P 〈0.05） Before and after surgery, the low grade glioma group CD4＋/CD8＋ was significantly higher than that in the high-grade gliomas group, CD8＋ was lower than the high grade glioma group （ P〈0.05）, and CD3＋ , CD4＋ , NK cell （CD56＋ ） no statistical difference （ P〈0.05） ; in the low grade glioma group, the median survival time was 32 months, and the median survival time in the high grade glioma group was 15 months, the difference between the two groups was statistically significant （ P〈0.05） ; in CD4＋/CD8＋〉1 group, the median survival time was 30 months,
出处
《医学临床研究》
CAS
2016年第8期1489-1491,共3页
Journal of Clinical Research
